| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3436 | 2014 |
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ... The Lancet 379 (9810), 39-46, 2012 | 998 | 2012 |
| Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) M Bolla, H van Poppel, B Tombal, K Vekemans, L Da Pozzo, ... The Lancet 380 (9858), 2018-2027, 2012 | 922 | 2012 |
| Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting L Dickinson, HU Ahmed, C Allen, JO Barentsz, B Carey, JJ Futterer, ... European urology 59 (4), 477-494, 2011 | 895 | 2011 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 871* | 2018 |
| Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer … M Guckenberger, Y Lievens, AB Bouma, L Collette, A Dekker, MS Nandita, ... The Lancet Oncology 21 (1), e18-e28, 2020 | 799 | 2020 |
| Adverse effects of androgen deprivation therapy and strategies to mitigate them PL Nguyen, SMH Alibhai, S Basaria, AV D’Amico, PW Kantoff, NL Keating, ... European urology 67 (5), 825-836, 2015 | 799 | 2015 |
| Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Parker, E Castro, K Fizazi, A Heidenreich, P Ost, G Procopio, B Tombal, ... Annals of Oncology 31 (9), 1119-1134, 2020 | 758 | 2020 |
| Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, ... New England Journal of Medicine 381 (26), 2506-2518, 2019 | 624 | 2019 |
| Prevention and early detection of prostate cancer J Cuzick, MA Thorat, G Andriole, OW Brawley, PH Brown, Z Culig, ... The lancet oncology 15 (11), e484-e492, 2014 | 619 | 2014 |
| Darolutamide and survival in metastatic, hormone-sensitive prostate cancer MR Smith, M Hussain, F Saad, K Fizazi, CN Sternberg, ED Crawford, ... New England Journal of Medicine 386 (12), 1132-1142, 2022 | 617 | 2022 |
| Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of … CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ... The lancet oncology 17 (2), 243-256, 2016 | 496 | 2016 |
| Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and … RJ Sylvester, MA Brausi, WJ Kirkels, W Hoeltl, FC Da Silva, PH Powell, ... European urology 57 (5), 766-773, 2010 | 484 | 2010 |
| Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 476 | 2017 |
| Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical … A Bex, P Mulders, M Jewett, J Wagstaff, JV Van Thienen, CU Blank, ... JAMA oncology 5 (2), 164-170, 2019 | 475 | 2019 |
| Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label … K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, ... The Lancet 399 (10336), 1695-1707, 2022 | 443 | 2022 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 420 | 2017 |
| Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist PC Albertsen, L Klotz, B Tombal, J Grady, TK Olesen, J Nilsson European urology 65 (3), 565-573, 2014 | 399 | 2014 |
| Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised … M Smith, C Parker, F Saad, K Miller, B Tombal, QS Ng, M Boegemann, ... The Lancet Oncology 20 (3), 408-419, 2019 | 389 | 2019 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 385 | 2015 |
